Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Viva Biotech Holdings ( (HK:1873) ) has provided an announcement.
Viva Biotech Holdings has convened its annual general meeting for June 26, 2026, in Shanghai to seek shareholder approval on a range of standard corporate matters. Shareholders will be asked to receive the audited financial statements for the year ended December 31, 2025, re-elect three directors, and authorize the board to set directors’ remuneration.
The meeting will also consider re-appointing Ernst & Young as the company’s auditor and giving the board a renewed mandate to issue additional shares and related securities up to 20 per cent of the current issued share capital. This authority, if granted, would provide the company with flexibility to raise capital and pursue strategic initiatives, potentially affecting its capital structure and future financing plans.
More about Viva Biotech Holdings
Viva Biotech Holdings is a Hong Kong-listed company incorporated in the Cayman Islands and operating in the biotechnology and pharmaceutical services sector. The group provides drug discovery and related biotech services through its subsidiaries, serving pharmaceutical and life sciences clients from its facilities in Shanghai and other locations.
Average Trading Volume: 9,655,165
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.83B
For an in-depth examination of 1873 stock, go to TipRanks’ Overview page.